A144510 Share Price Performance
Recent A144510 News & Updates
No updates
GC Cell Corporation Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -5.47k
- Gross Margin
- 18.01%
- Net Profit Margin
- -47.56%
- Debt/Equity Ratio
- 14.9%
GC Cell Corporation Competitors
About A144510
- Founded
- 2011
- Employees
- 752
- CEO
- WebsiteView website
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.
South Korean Market Performance
- 7 Days: 1.5%
- 3 Months: 24.6%
- 1 Year: 13.5%
- Year to Date: 32.5%
The market is up 1.5% over the last week, with the Information Technology sector leading the way, up 5.3%. The market is up 14% over the last 12 months. As for the next few years, earnings are expected to grow by 21% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading